Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $1M
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| BOL-DP-o-04 + SCO | Phase 2 | Low Back Pain |
| dapivirine 4789 | Phase 2 | HIV-1 Infections |
| dapivirine (TMC120) vaginal gel | Phase 2 | HIV Infections |
| Lozanoc | Phase 2 | Neutropenia |
| GXCPC1 | Phase 2 | Knee Osteoarthritis |
| GXNPC1 | Phase 2 | Chronic Stroke |
| Ivermectin 0.5% Topical Application Lotion | Phase 3 | Head Lice |
| Dapivirine Vaginal Ring | Phase 2 | Human Immunodeficiency Virus |
| dapivirine | Phase 2 | HIV Infections |
| Dapivirine Vaginal Ring-004 | Phase 3 | HIV Prevention |
| Umbilical Cord Mesenchymal Stem Cell (UC-MSC) | Phase 2 | Retinitis Pigmentosa |
| Permethrin Cream, 5% | Phase 3 | Scabies |
Daily closes through 2026-05-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.